Antipseudomonal treatment decisions during CF exacerbation management

Published:April 21, 2022DOI:


      • Exacerbation treatment outcomes for STOP2 subjects with P. aeruginosa were studied.
      • Outcomes were compared across number of antipseudomonal classes used.
      • Lung function and symptom changes and future exacerbation risks were compared.
      • Patients receiving one class fared no worse than those receiving two or more classes.



      Cystic fibrosis (CF) pulmonary exacerbation (PEx) treatment guidelines suggest that Pseudomonas aeruginosa (Pa) airway infection be treated with two antipseudomonal agents.


      We retrospectively studied treatment responses for STOP2 PEx treatment trial (NCT02781610) participants with a history of Pa infection. Mean lung function and symptom changes from intravenous (IV) antimicrobial treatment start to Visit 2 (7 to 10 days later) were compared between those receiving one, two, and three+ antipseudomonal classes before Visit 2 by ANCOVA. Odds of PEx retreatment with IV antimicrobials within 30 days and future IV-treated PEx hazard were modeled by logistic and Cox proportional hazards regression, respectively. Sensitivity analyses limited to the most common one-, two-, and three-class regimens, to only IV/oral antipseudomonal treatments, and with more stringent Pa infection definitions were conducted.


      Among 751 participants, 50 (6.7%) were treated with one antipseudomonal class before Visit 2, while 552 (73.5%) and 149 (19.8%) were treated with two and with three+ classes, respectively. Females and participants with a negative Pa culture in the prior month were more likely to be treated with a single class. The most common single, double, and triple class regimens were beta-lactam (BL; n = 42), BL/aminoglycoside (AG; n = 459), and BL/AG/fluoroquinolone (FQ; n = 73). No lung function or symptom response, odds of retreatment, or future PEx hazard differences were observed by number of antipseudomonal classes administered in primary or sensitivity analyses.


      We were unable to identify additional benefit when multiple antipseudomonal classes are used to treat PEx in people with CF and Pa.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Konstan M.W.
        • Morgan W.J.
        • Butler S.M.
        • Pasta D.J.
        • Craib M.L.
        • Silva S.J.
        • Stokes D.C.
        • Wohl M.E.
        • Wagener J.S.
        • Regelmann W.E.
        • Johnson C.A.
        • Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
        Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.
        J Pediatr. 2007; 151 (Aug139.e1): 134-139
        • Konstan M.W.
        • Wagener J.S.
        • VanDevanter D.R.
        • Pasta D.J.
        • Yegin A.
        • Rasouliyan L.
        • Morgan W.J.
        Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.
        J Cyst Fibros. 2012; 11 (Sep): 405-411
        • Liou T.G.
        • Adler F.R.
        • Fitzsimmons S.C.
        • Cahill B.C.
        • Hibbs J.R.
        • Marshall B.C.
        Predictive 5-year survivorship model of cystic fibrosis.
        Am J Epidemiol. 2001; 153: 345-352
        • Mayer-Hamblett N.
        • Rosenfeld M.
        • Emerson J.
        • Goss C.H.
        • Aitken M.L.
        Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
        Am J Respir Crit Care Med. 2002; 166: 1550-1555
        • Ratjen F.
        • Döring G.
        Cystic fibrosis.
        Lancet. 2003; 361 (Feb 22Review): 681-689
        • Treatment of pulmonary exacerbation of cystic fibrosis
        Clinical practice guidelines for cystic fibrosis.
        Cystic Fibrosis Foundation, Bethesda, MD1997
        • Flume P.A.
        • Mogayzel P.J.
        • Robinson K.A.
        • Goss C.H.
        • Rosenblatt R.L.
        • Kuhn R.J.
        • Marshall B.C.
        • Clinical Practice Guidelines for Pulmonary Therapies Committee
        Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
        Am J Respir Crit Care Med. 2009; 180: 802-808
        • Elphick H.E.
        • Scott A.
        Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
        Cochrane Database Syst Rev. 2016; 12 (Dec 1)CD002007
        • Holland P.
        • Jahnke N.
        Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
        Cochrane Database Syst Rev. 2021; 6 (Jun 23)CD002007
        • McLaughlin F.J.
        • Matthews W.J.
        • Strieder D.J.
        • Sullivan B.
        • Taneja A.
        • Murphy P.
        • Goldmann D.A.
        Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.
        J Infect Dis. 1983; 147 (Mar): 559-567
        • Padoan R.
        • Cambisano W.
        • Costantini D.
        • Crossignani R.M.
        • Danza M.L.
        • Trezzi G.
        • Giunta A.
        Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
        Pediatr Infect Dis J. 1987; 6 (Jul): 648-653
        • Smith A.L.
        • Doershuk C.
        • Goldmann D.
        • Gore E.
        • Hilman B.
        • Marks M.
        • Moss R.
        • Ramsey B.
        • Redding G.
        • Rubio T.
        • Williams-Warren J.
        • Wilmott R.
        • Wilson H.D.
        • Yogev R.
        Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.
        J Pediatr. 1999; 134 (Apr): 413-421
        • Master V.
        • Roberts G.W.
        • Coulthard K.P.
        • Baghurst P.A.
        • Martin A.
        • Roberts M.E.
        • Onishko C.R.
        • Martin A.J.
        • Linke R.J.
        • Holmes M.
        • Jarvinen A.
        • Kennedy D.
        • Colebatch K.A.
        • Hansman D.
        • Parsons D.W.
        Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
        Pediatr Pulmonol. 2001; 31 (May): 367-376
        • Balke B.
        • Hogardt M.
        • Schmoldt S.
        • Hoy L.
        • Weissbrodt H.
        • Häussler S.
        Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
        Eur J Clin Microbiol Infect Dis. 2006; 25 (Jan): 25-30
        • Smith S.
        • Ratjen F.
        • Remmington T.
        • Waters V.
        Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
        Cochrane Database Syst Rev. 2020; 5 (May 15)CD006961
        • Aaron S.D.
        Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
        Paediatr Respir Rev. 2007; 8 (Sep): 256-261
        • Harruff E.E.
        • Kil J.
        • Ortiz M.G.T.
        • Dorgan D.
        • Jain R.
        • Poth E.A.
        • Fifer R.C.
        • Kim Y.J.M.
        • Shoup A.G.
        • Flume P.A.
        Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: ototoxicity following tobramycin treatment.
        J Cyst Fibros. 2021; 20 (Mar): 288-294
        • LeCleir L.K.
        • Pettit R.S.
        Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
        Pediatr Pulmonol. 2017; 52 (Aug): 1000-1005
        • Goss C.H.
        • Heltshe S.L.
        • West N.E.
        • Skalland M.
        • Sanders D.B.
        • Jain R.
        • Barto T.L.
        • Fogarty B.
        • Marshall B.C.
        • VanDevanter D.R.
        • Flume P.A.
        • STOP2 Investigators
        A randomized trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment.
        Am J Respir Crit Care Med. 2021; (Sep 1Epub ahead of print. PMID: 34469706)
        • VanDevanter D.R.
        • Morris N.J.
        • Konstan M.W.
        IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
        J Cyst Fibros. 2016; 15 (May): 372-379
        • Flume P.A.
        • Wainwright C.E.
        • Tullis D.E.
        • Rodriguez S.
        • Niknian M.
        • Mark M.
        • Davies J.C.
        • Wagener J.S.
        Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
        J Cyst Fibros. 2018; 17: 83-88
        • Cogen J.D.
        • Faino A.V.
        • Onchiri F.
        • Hoffman L.R.
        • Kronman M.P.
        • Nichols D.P.
        • et al.
        Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations.
        Clin Infect Dis. 2021; 73 (Jun 8): 1589-1596
        • Paul M.
        • Benuri-Silbiger I.
        • Soares-Weiser K.
        • Leibovici L.
        Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.
        BMJ. 2004; 328 (Mar 20): 668
        • Jiang M.
        • Karasawa T.
        • Steyger P.S.
        Aminoglycoside-induced cochleotoxicity: a review.
        Front Cell Neurosci. 2017; 11 (Oct 9): 308